Fate Therapeutics, Inc.
FATE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$32,250 | -$34,070 | -$37,621 | -$52,153 |
| Dep. & Amort. | $3,227 | $3,278 | $3,333 | $4,813 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $4,861 | $7,154 | $7,381 | $9,120 |
| Change in WC | $504 | $73 | -$5,373 | -$1,909 |
| Other Non-Cash | -$716 | -$1,022 | -$1,529 | $12,330 |
| Operating Cash Flow | -$24,374 | -$24,587 | -$33,809 | -$27,799 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$2,203 | -$1,362 | -$1,196 | -$98 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$57,975 | -$50,813 | -$48,624 | -$38,005 |
| Inv. Sales/Matur. | $81,447 | $71,644 | $92,493 | $60,919 |
| Other Inv. Act. | $3 | $122 | $0 | $0 |
| Investing Cash Flow | $21,272 | $19,591 | $42,673 | $22,816 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $2,475 | $1,325 | $0 | $3,130 |
| Financing Cash Flow | $2,475 | $1,325 | $0 | $3,130 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$627 | -$3,671 | $8,864 | -$1,853 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $51,476 | $55,147 | $46,283 | $48,136 |
| End Cash | $50,849 | $51,476 | $55,147 | $46,283 |
| Free Cash Flow | -$26,577 | -$25,949 | -$35,005 | -$27,897 |